TRANSLATIONAL RELEVANCE:
For more than 50 years, the basic paradigm that vaccination with chemically induced tumor cells is effective at protecting mice with a challenge from that specific tumor, but not other tumors induced by the same carcinogen, has been repeatedly documented, is well accepted and has driven numerous autologous cancer vaccine trials. The importance of the current paper is that it identifies a methodology that improves vaccine efficacy sufficiently enough to prime immunity against shared antigens in models where whole tumor vaccines fail to do so.
It also provides the mechanisms responsible for augmented priming and insights to further enhancements. Better vaccines will help, but generating therapeutic immune responses in patients with advanced cancer will likely require a multimodality combination approach. A clinical study of this strategy is underway.
INTRODUCTION
Cross-presentation was identified as a means by which antigens can be presented by cells in which they were not synthesized, thus obviating direct presentation as the sole mechanism to prime an immune response (1) . These findings were expanded by the demonstration that cross-presentation of melanoma antigens during vaccination was essential for the generation of an effective anti-tumor immune response (2) . One component of crosspresentation that has been debated and still remains unknown is the source of antigen and the method of its delivery to professional antigen-presenting cells (pAPC). While some groups have shown that the source of antigen is cellular protein, others argue that it is peptides chaperoned by heat-shock proteins (HSPs) (3, 4) . To complicate the debate further, Despite their discrete biophysical properties both dendritic cell-derived exosomes and tumorderived autophagosomes can generate robust immune responses (12) . However, unlike tumor-derived autophagosomes, tumor-derived exosomes have been demonstrated by different groups to be immunosuppressive via a variety of mechanisms (9, 10, 13, 14) .
A key marker of the induction of autophagy is the conversion of the cytosolic form of microtubule-associated protein 1 light chain 3 (LC3-I) via a series of ubiquitin-like conjugation steps to the lipidated form (LC3-PE or LC3-II) that is tightly associated with autophagosomes. Conversion to LC3-II is not only a definitive marker of autophagy but it can promote curvature and hemifusion of membranes, and is therefore critical to the process (15) . A recently described protein, p62/SQSTM1 (sequestosome), binds both polyubiquitin and LC3 and thus facilitates degradation of ubiquitinated proteins via autophagy (16, 17) .
Interaction of LC3 with p62 has added a layer of complexity to the autophagic network and suggests that this bulk degradation process may be more selective than previously appreciated.
We have shown that autophagy in tumor cells is essential for efficient crosspresentation and subsequent induction of tumor immunity in a B16 melanoma model (8) .
Cross-presentation, which was measured by proliferation of CFSE-labeled antigen-specific T cells, was significantly inhibited when autophagy was blocked and increased when autophagy was promoted. Interestingly, when cell lysates were fractionated and used as an antigen source, the fraction with the greatest cross-presentation activity also had the highest level of the specific autophagosome marker LC3. By treating cells with the proteasome inhibitor, bortezomib, and the lysosomotropic agent, NH 4 Cl, which prevents fusion of autophagosomes with lysosomes, autophagosome-containing vesicles could be isolated.
These isolated autophagosome-containing vesicles, termed DRibbles (7) served as a potent antigen source in cross-presentation assays and in in vivo vaccine studies. In combination with the results of two recent publications, which demonstrated enhanced antigen presentation related to autophagy (18, 19) , our work has further defined the function of autophagy as a means of sequestering antigen for cross-presentation.
To understand better the function of autophagy in cross-presentation, we developed a model that incorporates the DRiP hypothesis (20) . A significant proportion of MHC class I binding peptides originate from defective ribosomal products (DRiPs), including misfolded and truncated polypeptides, which are degraded by the proteasome shortly after their translation and loaded onto MHC class I molecules (5) . Since DRiPs, as well as other shortlived proteins (SLiPs), are stabilized by proteasome inhibition, we hypothesized that autophagosome-containing vesicles isolated from bortezomib-treated cells would contain DRiPs and SLiPs and thereby provide a unique spectrum of potential tumor rejection antigens. We further hypothesized that using these vesicles to prime an immune response will generate a broader T-cell response.
Prehn and Main established the unique specificity of chemically induced 3-methycholanthrene (MCA) sarcomas, whereby sarcomas generated in genetically identical mice with similar morphology and growth characteristics would only protect vaccinated mice from a challenge with the immunizing tumor but not other syngeneic sarcomas. While there has been a paucity of antigens associated with the unique specificity of this tumor model deletion in a region rich with oncogenes and tumor suppressor genes (22) . Even though a unique immunodominant antigen results from each MCA treatment, this data demonstrates that specific loci or chromosomal regions are more susceptible to the mutating effects of MCA. Moreover, using CTL immunoselection, a secondary tumor antigen shared by an independent sarcoma cell line was uncovered, demonstrating that the unique rejection antigen is only part of the tumor antigen profile (23) . Others have demonstrated cross-reactivity among heterogenic clones of the MCA-106 sarcoma using effector cells primed with the parental MCA-106 line but no cross-reactivity with an "antigenically" distinct MCA-205 sarcoma (24) . There are therefore limited examples of common antigens among the MCAinduced sarcomas in the few publications reported.
In this paper, we examine the role of autophagy in tumor immunity by focusing on autophagosomes as the source of antigen for cross-presentation. We find that vaccination with antigens derived from autophagosomes can broaden the T-cell response beyond that seen following whole cell vaccination. Studies using MCA sarcomas as well as HEK 293T cells stably expressing a short-lived model antigen both indicate that short-lived proteins are necessary for this unique autophagosome-mediated immune response. Further, we demonstrate that the ubiquitin/LC3-binding protein p62 (sequestosome) has a key role as a regulator of selective autophagy, as it associates with both ubiquitinated antigen and LC3 and is needed for the sequestration of SLiPs into the autophagosomes. Based on these findings, we propose that the broad array of tumor antigens contained in autophagosomes is dependent upon ubiquitinated SLiPs incorporated by the sequestosome and that cross-presentation of these autophagosomes primes a unique cross-protective immune response. 
MATERIALS AND METHODS

Mice and cell lines
Female C57BL/6J (B6) mice were purchased from Charles River (Wilmington, MA). OT-1 breeders transgenic for the TCR that recognizes chicken ovalbumin (peptide sequence SIINFEKL) in the context of H-2K b were purchased from Jackson Laboratory (Bar Harbor, ME). All mice were maintained and used in accordance with the Earl A. Chiles Research Institute Animal Care and Use Committee and recognized principles of laboratory animal care were followed (Guide for the Care and Use of Laboratory Animals, National Research Council, 1996).
Human embryonic kidney 293T cells were cultured in complete medium (CM), which consisted of DMEM (Lonza) supplemented with 10% FBS (Life Technologies, Grand Island, New York). Cell lines were maintained in T-75 or T-150 culture flasks in a 5% CO2 incubator at 37°C. Stable expression of both the stable OVA (mOVA) and short-lived OVA (rOVA) in HEK 293T cells was achieved with lentiviral transduction as described earlier (8) . 3-Methylcholanthrene (MCA)-induced sarcomas were previously generated in our laboratory (25, 26) . All tumors aliquots used had been in vivo passaged less than 6 times. Unique MCA sarcomas were passaged in vivo by excising a tumor from a female C57BL/6 mouse followed by triple enzyme digestion of the tumor (incubation at room temperature with hyaluronidase, collagenase and DNAse for 1-3 hours with agitation) and subcutaneous injection into a naïve mouse. Uniqueness of each sarcoma was confirmed by vaccine challenge studies summarized in figure 2G . B16BL/6J-D5 (D5), a poorly immunogenic subclone of the spontaneously arising B16BL6 melanoma, was kindly provided by Dr. S. Shu (Earle A. Chiles Research Institute, Portland, Oregon). A stock of D5 cells, screened to be free of mycoplasma, were banked and assayed for immunogenicity and expression of melanoma-associated antigens, gp100 and TRP2. D5 cells from this stock were used within 4-6 weeks of culture. D5 cells were cultured in complete medium (CM), which consisted of RPMI 1640 (BioWhittaker,Walkersville, Maryland) supplemented with 10% FBS (Life Technologies, Grand Island, New York), 50μM 2-mercaptoethanol (Aldrich, Milwaukee, Wisconsin), 0.1mM non-essential amino acids, 1 mM sodium pyruvate, 2mM L-glutamine and 50μg/mL gentamicin sulfate. Cell lines were maintained in T-75 or T-150 culture flasks in a 5% CO2 incubator at 37°C.
Antigen presenting cells (APC) were generated in the spleens of C57BL6 mice via hydrodynamic gene transfer (27) . (8, 28, 29) . Spleens were harvested and processed into a single cell suspension and frozen.
Tumor vaccine and challenge
Female C57BL/6J mice were vaccinated in the lower right flank with a subcutaneous injection of 5x10 6 irradiated tumor cells from a freshly digested sarcoma or with 3x10 6 APCs pulsed with autophagosomes (3x10 6 cell equivalents (CE)) for 6-8 hours. To control for the use of dendritic cells in the autophagosome vaccine, 3x10 6 APCs pulsed with 5x10 6 irradiated tumor cells for 6 hours, were washed and used as a vaccine as described above. 
DNA Construction and Transfection
Plasmid DNA vector cloning was described earlier (8) . Briefly, Ub-X-GFP-expressing 
Statistical Methods
For the time-to-death endpoint, the survival distribution was estimated using the KaplanMeier method. The log-rank test was used to compare the hazard rates of the vaccines. For ELISA data, the log 10 -transformed IFN-γ values were analyzed using a mixed effects model that appropriately accounted for different sources of variability introduced by the experimental design. This model had fixed effects for the vaccine group, stimulator, and their interaction, and random effects for the experiment (nested within vaccine group), the stimulator pool interaction, and the assay replicate. Different variances were allowed for each vaccine group. Contrasts using least squares means for each stimulator-vaccine group combination were used to test for mean differences. A significance level of α=0.05 between different vaccine groups was limited to individual stimulators. The significance level was α=0.05. All analyses were done using SAS v9.2 using either PROC LIFETEST or PROC
MIXED.
Research. Earlier experiments demonstrated that autophagosomes pulsed onto APCs were more effective than autophagosomes alone at generating a productive vaccine (data not shown). 
To further define the relationship of short-lived proteins and autophagosomes, cells were pretreated with the protein synthesis inhibitor cyclohexamide (CHX) before the addition of bortezomib to inhibit the production of short-lived proteins and prevent their inclusion into autophagosomes. To determine a dose of CHX capable of preventing protein synthesis, HEK 293T cells were depleted of all methionine and then treated with CHX at 10 μg/mL or 50 μg/mL, or with vehicle alone for 4 hours. Concomitantly, the cells were pulsed with a non-radioactive labeled methionine (L-azidohomoalanine) and visualized using a streptavidin-HRP-enzymatic reaction. The HRP detection system can react with endogenous biotin, such as the biotin carboxylase subunits of acetyl-CoA (39 KDa band in Figure 4A ). 10ug/mL in 4 hours of cyclohexamide prevented synthesis of all proteins ( Figure 4A ).
We hypothesized that since mOVA is a stable protein, its expression would be 
The expression of both mGFP-OVA and rGFP-OVA in HEK 293T cell lysates was also examined by western blot after a 24 hour treatment. Similar to what was observed by flow cytometry, bortezomib caused a modest increase in the more stable mOVA protein.
However, HEK 293mGFP-OVA cells cultured overnight with CHX and bortezomib exhibited a substantial reduction in the levels of the 64 KDa fusion protein ( Figure 4C ).
Bortezomib increased the half-life of the rGFP-OVA fusion protein in HEK 293rGFP-OVA cells only in the absence of CHX.
Autophagosomes derived from cells that lack short-lived proteins have diminished capacity to stimulate antigen-specific T cells.
Autophagosomes derived from cells expressing either the short-lived rGFP-OVA protein or the stable mGFP-OVA protein were isolated, used to pulse APCs and drive naïve antigen-specific OT-1 T-cell proliferation. Autophagosomes from cells expressing the stable mGFP-OVA protein caused OT-1 T cells to proliferate at nearly the same level whether they were generated in the presence or absence of bortezomib, with or without CHX ( Figure 4D ).
These data indicate that CHX pretreatment does not prevent stable proteins from being sequestered in autophagosomes nor does it prevent the formation of "functional" autophagosomes. However, autophagosomes from CHX-treated HEK 293rGFP-OVA cells were unable to induce antigen-specific T-cell proliferation ( Figure 4E ). The diminished proliferation was more apparent when higher doses of autophagosomes were used to stimulate the naïve T cells. These experiments demonstrate that stable proteins, but not mg/mL and 2.15 mg/mL respectively). To assess the potential negative effects of CHX on autophagy, which could limit more than just the incorporation of SLiPs and DRiPs into autophagosomes, LC3, a critical component necessary for the induction of autophagy and thus autophagosome formation, was measured by western blot. The ratio of LC3 to total protein was the same or even greater with CHX pretreatment in both HEK293mGFP-OVA ( Figure 6A ) and MCA-304 autophagosomes ( Figure 5C ).
Autophagosomes contain ubiquitinated proteins and the sequestosome/p62, both of which co-localize with LC3.
To examine the effects of CHX on protein incorporation into autophagosomes, expression of mGFP-OVA and rGFP-OVA in isolated autophagosomes was determined by western blot. Autophagosomes isolated from HEK 293mGFP-OVA cells had nearly the same expression of mGFP-OVA regardless of treatment with bortezomib or CHX ( Figure   6A ). Interestingly, the autophagosomal marker LC3 was overexpressed in the CHX-treated cells relative to the +/-bortezomib groups ( Figure 6A ). This increase in LC3 has been It is also of note that while the cellular expression of mGFP-OVA pre-treated with CHX was reduced ( Figure 4C ), its expression in the autophagosome-containing vesicles was not ( Figure 6A ). This suggests that mOVA-containing autophagosomes blebbed from the cells, reducing the cellular expression of this fusion protein while maintaining its expression in the autophagosomes. The model short-lived protein, rGFP-OVA, was detected only if the proteasome was inhibited in cells with normal protein synthesis; it was absent in autophagosomes produced from cells treated with CHX. Therefore, by inhibiting protein synthesis before blocking the proteasome, isolated autophagosomes contain minimal amounts of short-lived protein.
Since SLiPs were a critical component of the autophagosome vaccine ( Figures 4E and   5 ), we were interested in how they were delivered to the autophagosomal pathway. Our hypothesis predicts and others have shown (8) that treating cells with bortezomib increases the pool of ubiquitinated proteins, which may provide a means of delivery to the autophagosomal pathway. Interestingly, higher molecular weight bands were detected with anti-GFP in HEK 293rGFP-OVA autophagosomes isolated from bortezomib-treated cells ( Figure 6A ), but not in the cells used to produce the autophagosomes ( Figure 4B ). Although these high weight bands were also present in autophagosomes isolated from cells expressing the more stable mGFP-OVA protein, they were less abundant. The N-end rule predicts that the model short-lived protein will be quickly degraded in a ubiquitin-proteasome-dependent fashion (34) . We therefore hypothesized that these larger proteins were a ubiquitinated species of the fusion protein that escaped degradation by the proteasome and were enriched Recent work has demonstrated that the ubiquitin-binding protein sequestosome/p62 can interact with both ubiquitinated proteins and autophagy-related initiator LC3, potentially delivering these proteins to the autophagy pathway (16, 17, 35) . Western blots showed clearly that p62 was present in the autophagosomes ( Figure 6C ). Co-localization of LC3 and p62 in HEK 293 T cells was seen with confocal microscopy using GFP-tagged LC3 and tomato-tagged p62. The short-lived protein, rGFP-OVA, also co-localized with tomatotagged p62 in transfected HEK 293 T cells but not with a control GFP vector ( Figure 6D ).
These results demonstrate that ubiquitinated proteins are packaged into autophagosomes with ubiquitin/LC3 binding protein p62, especially when cells are treated with bortezomib.
p62 is necessary for the delivery of ubiquitinated proteins to autophagosomes.
To understand how the sequestosome may influence trafficking of specific proteins to autophagosomes, p62 expression was knocked down in HEK 293T cells. A titration of p62 siRNA showed that protein expression was greatly reduced with 50 nM of the p62 smart pool Based on the co-localization experiments and the presence of the ubiquitinated protein species in isolated autophagosomes, we hypothesized that knockdown of the sequestosome would greatly diminish the ability of autophagosomes to stimulate naive T cell proliferation. To test this hypothesis, autophagosomes generated from the co-transfection described above were pulsed onto APCs and used to stimulate CFSE-labeled naive antigen specific T cells as previously described. T cells stimulated with autophagosomes generated from 293 cells with the p62 knockdown proliferated less than those stimulated without the knockdown ( Figure 7C 
DISCUSSION
We have demonstrated that an autophagosome vaccine can prime a repertoire of T cells with a broader tumor-specific reactivity than the intact sarcoma from which it was derived. In contrast to the irradiated whole cell vaccine, vaccination with tumor-derived autophagosomes protected mice from a challenge with independently-derived MCA sarcomas. Experiments using MCA sarcomas, or the OVA model antigen system, both suggest that short-lived proteins incorporated into autophagosomes are necessary in generating a robust immune response. Additionally, these data suggest that the sequestering of SLiPs into autophagosomes is dependent on the ubiquitin binding protein sequestosome/p62. This novel vaccine strategy has redefined the tumor rejection antigens associated with MCA-induced tumors and has created the potential for new vaccine strategies.
While MCA-induced sarcomas can share similar histology, growth patterns, sensitivity to chemotherapeutics and are generated in syngeneic mice using the same carcinogen, each sarcoma induces a unique tumor-specific immune response. This observation has been made by many researchers (31, 33, (36) (37) (38) , and it is also evident in our studies by the failure of our MCA-induced sarcoma whole cell vaccine to cross-protect against independently derived but related MCA-induced sarcomas ( Figure 1A ). While this failure to cross-protect has been attributed to each sarcoma's unique antigenic profile (38) , it seems unlikely that a large panel of sarcomas of similar etiology will not have common antigens. A more plausible description of this unique specificity could be described by the concept of a tumor rejection antigen, which functionally relates to how well an immune 
altering the tumor specificity with an autophagosome vaccine. Based on the observation that both protection and cross protection from an MCA sarcoma challenge were reduced with elimination of SLiPs from the autophagosome vaccine ( Figure 5 ), antigens common to independently derived MCA-induced sarcomas are likely to be SLiPs. These SLiPs may provide epitopes with a high affinity for MHC molecules allowing them to compete with the dominant whole cell rejection antigen for surface density on the APC. Alternatively, the dominant rejection antigen may not be sequestered into autophagosomes, providing subdominant, neo or cryptic antigens access to MHC molecules for cross presentation. APC pulsed with different quantities of either purified autophagosomes or total cell lysates and co-cultured for 3 days at 37°C. Proliferation of T cells was measured by CFSE dilution as done previously. n=1 experiment. 
